Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Year range
1.
Arq. neuropsiquiatr ; 77(6): 442-444, June 2019. graf
Article in English | LILACS | ID: biblio-1011357

ABSTRACT

ABSTRACT Duchenne de Boulogne is known mainly by the disease eponymously named "Duchenne muscular dystrophy", or pseudohypertrophic muscular dystrophy, although some experts consider that the original description of this disease does not belong to him. Less well known are the facts related to the tragic death of his beloved wife shortly after the birth of his only child, the unjustifiable distance he was forced to keep from this son for more than 30 years, and of being humiliated and professionally despised by his peers. These events made the life of this physician, physiologist, researcher and inventor extremely arduous. We emphasize some aspects of the history of this man, his work and his life, a true genius of few friends.


RESUMO Duchenne de Boulogne é conhecido por muitos principalmente devido à doença que leva seu nome - doença de Duchenne ou Distrofia Muscular Pseudo-hipertrófica - embora alguns historiadores considerem que a descrição original desta doença não lhe pertence. Menos conhecidos são os fatos relacionados à morte trágica de sua amada esposa logo após o nascimento de seu filho, o afastamento injusto que foi forçado a manter deste filho único por mais de 30 anos, e ser humilhado e profissionalmente desprezado por seus pares da comunidade neurológica, que em conjunto tornaram a vida desse médico, fisiologista, pesquisador e inventor, extremamente árdua. Enfatizamos alguns aspectos da história deste homem, seu trabalho e ocaso, protótipo de um verdadeiro gênio de poucos amigos.


Subject(s)
History, 19th Century , Electrophysiology/history , Neurology/history , Muscular Dystrophy, Duchenne/history , France
2.
Rev. méd. Panamá ; 39(3): 100-105, 2019. ilus, tab
Article in Spanish | LILACS | ID: biblio-1100424

ABSTRACT

Las distrofias musculares de origen genético son muy diversas y, tanto su diagnóstico preciso como su manejo, suponen un reto importante. En cuanto a este último aspecto, no obstante el desarrollo en proceso de nuevas estrategias a nivel molecular para su tratamiento, las herramientas con que se cuenta para este propósito son limitadas, y pocas veces pueden influir de manera efectiva para evitar el deterioro progresivo que muchos de estos pacientes experimentan. Además, las terapias de última generación no abarcan la gran diversidad de estas patologías y no se espera que estén disponibles a corto plazo para la mayoría de los pacientes. El propósito del artículo es mostrar el papel de las poliaminas, actores ubicuos en el metabolismo in­ tracelular tal vez poco conocidos; cómo están involucrados en los procesos fisiológicos y patológicos, y cómo también pudiesen estar involucrados en la fisiopatología de las distrofias musculares. Su inhi­bición controlada, mediante Difluorometilornitina (DFMO), pudiese constituir un mecanismo para en­ lentecer o eliminar el deterioro muscular de estos pacientes, al utilizarse como una herramienta dentro del arsenal de las ya existentes


Muscular dystrophies of genetic origin are very diverse and, both their precise diagnosis and their management represent an important challenge. Regarding this last aspect, despite the development in process of new strategies at the molecular level for its treatment, the tools available for this pur­ pose are limited, and can rarely influence effectively to avoid the progressive deterioration that many of these patients experience. In addition, the lates t­generation therapies do not cover the great diversity of these pathologies and are not expected to be available in the short term for most patients. The purpose of the article is to show the role of polyamines, ubiquitous actors in intracellular meta­ bolism, perhaps little known; how they are involved in physiological and pathological processes, and how they could also be involved in the physiopathology of muscular dystrophies. Its controlled inhi­ bition, by difluoromethylilitin (DFMO), could be a mechanism to slow or eliminate the muscle deterio­ ration of these patients, by being used as a tool within the arsenal of those already existing.


Subject(s)
Humans , Male , Female , Ornithine/pharmacology , Polyamines/pharmacology , Muscular Dystrophies/diagnosis , Polyamines/chemistry , Chemical Compounds , Muscular Dystrophy, Duchenne/history , Muscular Dystrophy, Duchenne/prevention & control
3.
Arq. ciências saúde UNIPAR ; 3(3): 211-218, set.-dez. 1999.
Article in Portuguese | LILACS | ID: lil-284085

ABSTRACT

A Distrofia Muscular de Duchene (DMD) é um distúrbio genético que se caracteriza por uma degeneraçäo progressiva e irreversível da musculatura esquelética. A atuaçäo da Fisioterapia altera as perspectivas de qualidade e expectativa de vida. Assim, conhecer a doença favorece a elaboraçäo de objetivos e intervençäo de forma mais objetiva e eficiente. Nosso objetivo com este artigo foi fornecer conhecimentos básicos sobre a doença.


Subject(s)
Humans , Male , Female , Muscular Dystrophy, Duchenne/diagnosis , Physical Therapy Specialty , Muscular Dystrophy, Duchenne/physiopathology , Muscular Dystrophy, Duchenne/history
SELECTION OF CITATIONS
SEARCH DETAIL